Tolypomycin, a new antibiotic. V. In vitro and in vivo antimicrobial activity.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000188:drug therapy*; D002701:Chloramphenicol / Q000494:pharmacology; D002751:Chlortetracycline / Q000494:pharmacology; D004096:Dihydrostreptomycin Sulfate / Q000494:pharmacology; D004355:Drug Stability; D004917:Erythromycin / Q000494:pharmacology; D005750:Gastric Juice; D006863:Hydrogen-Ion Concentration; D007612:Kanamycin / Q000494:pharmacology; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D009675:Novobiocin / Q000494:pharmacology; D010403:Penicillin Resistance; D010406:Penicillins / Q000494:pharmacology; D011008:Pneumococcal Infections / Q000188:drug therapy; D012293:Rifampin / Q000494:pharmacology; D012996:Solutions; D013203:Staphylococcal Infections / Q000188:drug therapy; D013210:Staphylococcus / Q000187:drug effects; D013290:Streptococcal Infections / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D010406:Penicillins; D012996:Solutions; D009675:Novobiocin; D007612:Kanamycin; D004917:Erythromycin; D002701:Chloramphenicol; D004096:Dihydrostreptomycin Sulfate; D012293:Rifampin; D002751:Chlortetracycline